College of Pharmacy, Hubei University of Science and Technology, Xianning, Hubei, China.
School of Life Science and Technology, Wuhan Polytechnic University, Wuhan, Hubei, China.
Front Immunol. 2024 Nov 4;15:1481296. doi: 10.3389/fimmu.2024.1481296. eCollection 2024.
As an immune-related tumor type, bladder cancer has been attracting much attention in the study of its markers. In recent years, researchers have made rapid progress in the study of immune-related markers for bladder cancer. Studies have shown that immune-related markers play an important role in the diagnosis, prognosis assessment and treatment of bladder cancer. In addition, the detection of immune-related markers can also be used to evaluate the efficacy of immunotherapy and predict the treatment response of patients. Therefore, in depth study of the expression of immune-related markers in bladder cancer and their application in the clinic is of great significance and is expected to provide new breakthroughs for individualized treatment of bladder cancer. Future studies will focus more on how to detect immune-related markers with low cost and high accuracy, as well as develop new immunotherapeutic strategies to bring better therapeutic outcomes to bladder cancer patients.
作为一种免疫相关的肿瘤类型,膀胱癌在其标志物的研究中受到了广泛关注。近年来,研究人员在膀胱癌免疫相关标志物的研究方面取得了快速进展。研究表明,免疫相关标志物在膀胱癌的诊断、预后评估和治疗中发挥着重要作用。此外,免疫相关标志物的检测还可用于评估免疫治疗的疗效,并预测患者的治疗反应。因此,深入研究膀胱癌中免疫相关标志物的表达及其在临床中的应用具有重要意义,有望为膀胱癌的个体化治疗提供新的突破。未来的研究将更加关注如何以低成本、高精度的方式检测免疫相关标志物,以及开发新的免疫治疗策略,为膀胱癌患者带来更好的治疗效果。